CJC-1295 Buyer's Guide: 4 Decisions Before You Buy

Your pituitary gland does not release growth hormone in a steady stream. It fires in pulses, and those pulses are what make the whole system work.

Understanding why that matters requires a quick map of the growth hormone axis before you can make sense of any decision about CJC-1295.

The hypothalamus releases something called growth hormone releasing hormone, or GHRH, which is the signal that tells your pituitary to produce and release growth hormone. The pituitary responds to that signal with a sharp pulse of growth hormone into the bloodstream, and then a counter-signal called somatostatin comes in to shut the pulse off and bring levels back down. That oscillating pattern, pulses up and then back down, is what keeps the downstream machinery sensitive and responsive. Your liver reads those pulses and produces something called IGF-1, which is the actual tissue-level signal that drives most of the benefits people associate with growth hormone. The whole axis is designed around pulsatility, not flat elevation.

CJC-1295 is a synthetic analog of GHRH, which means it mimics the hypothalamus signal. It does not inject growth hormone into your body. It tells your pituitary to make its own. That distinction is the entire reason someone uses a secretagogue in the first place, because you are working within the system rather than replacing it.

Now you can understand the DAC question.

DAC stands for drug affinity complex, which is a modification attached to the CJC-1295 molecule that lets it bind to albumin, a protein naturally present in your blood, and extend its half life from a few minutes to around seven days. That sounds convenient because it means one or two injections per week instead of daily dosing. But what it actually produces is a continuous, flat elevation of GHRH activity rather than a sharp signal followed by a washout period.

Your pituitary is not designed to receive a constant GHRH signal. It is designed to receive a pulse, respond, and then reset. When GHRH is present continuously, the system does not keep firing at full capacity. It attenuates. The pulsatile pattern is not just aesthetically preferable, it is mechanistically required for the system to behave the way you want it to.

If a flat elevation of growth hormone activity is actually your goal, exogenous growth hormone does that better than CJC with DAC, and it comes with decades of clinical safety and dosing data behind it. The only version of CJC-1295 that preserves the purpose of using a secretagogue is the version without DAC.

The second question is about blended vials versus separate peptides, and this is mostly a math problem.

A common commercial blend puts five milligrams of CJC-1295 and five milligrams of Ipamorelin together in a single vial. When you reconstitute that with two milliliters of bacteriostatic water, every ten units on a standard insulin syringe delivers 250 micrograms of each compound. The blend works fine, but the math matters because if you ever need to adjust one compound independently of the other, blending them locks those ratios in place and you lose that flexibility.

The third decision, cycling, is where most of the pharmacological detail lives.

The standard protocol is three months on and one month off, and most people attribute that cycling requirement to the CJC side of the stack. It is not. It is driven entirely by the Ipamorelin.

Ipamorelin works through a different receptor pathway than CJC-1295. It binds to something called GHSR1a, which is the ghrelin receptor, and it mimics the ghrelin signal that acts as a second, complementary trigger for growth hormone release. That dual stimulation, GHRH from the CJC and ghrelin mimicry from the Ipamorelin, is why the combination produces a larger and more complete growth hormone pulse than either compound alone.

But ghrelin receptors have a vulnerability that GHRH receptors do not. When GHSR1a is stimulated continuously, the cell pulls those receptors off the surface through a process called beta-arrestin mediated internalization, which is essentially the cell reducing its own sensitivity by physically removing the receptor from where it can be activated. The longer you stimulate those receptors without a break, the fewer of them are available to respond. The practical result is that after roughly twelve to sixteen weeks of continuous use, IGF-1 levels can fall twenty to thirty percent from their peak even though you are still injecting the same dose. The dose has not changed. The number of available receptors has.

That receptor downregulation is what the off month is recovering. One month without ghrelin receptor stimulation allows the cell to restore receptor density and re-establish the sensitivity you started with.

The GHRH receptor side of this equation, the one CJC-1295 works through, does not have this problem. Tesamorelin, another GHRH analog, was run continuously for fifty-two weeks in the FDA clinical trials that led to its approval, and IGF-1 levels that were established by week twenty-six held steady all the way through week fifty-two. No attenuation. No cycling requirement. The GHRH pathway is substantially more durable than the ghrelin pathway under continuous stimulation.

So when you are planning your cycle, the month off is an Ipamorelin recovery period. The CJC is just along for the ride.

The last decision is about when secretagogues stop being the right tool.

Secretagogues work within your biology. Whatever growth hormone your pituitary is capable of producing, CJC and Ipamorelin help you produce more of it more effectively, and your feedback loop stays intact because somatostatin can still respond to the output and regulate it. You never exceed your own biological ceiling.

Exogenous growth hormone bypasses that ceiling entirely. It pushes blood growth hormone levels past what your pituitary would ever produce on its own, and your feedback loop reads that elevation and responds by suppressing the GHRH pathway through somatostatin release. One injection of exogenous growth hormone inhibits GHRH-stimulated growth hormone secretion by approximately eighty-six percent. That means the CJC in your system has almost no pathway left to work through. You are paying for a compound that cannot function because the very system it relies on has been shut down by the exogenous hormone.

This is not a dose optimization problem. It is a mechanism conflict. You cannot run both simultaneously and expect both to work.

What that means practically is that the two approaches represent two different decisions. Secretagogues are for optimizing within your own physiology, and they make sense as long as your goals are achievable within that ceiling. When the goal requires output your pituitary cannot produce regardless of how well stimulated it is, you are no longer in secretagogue territory. The tool that fits the goal changes, and trying to run both at once does not give you the benefits of either.

The pulsatility your pituitary was built around is not a quirk. It is the whole mechanism. Every good decision in this stack flows from understanding that one thing.

---

References

1. FDA Prescribing Information. EGRIFTA (tesamorelin). 2025 — 52-week continuous dosing, IGF-1 levels maintained at week-26 levels through week 52
2. Bowers CY et al. On the in vitro and in vivo activity of a new synthetic hexapeptide. Endocrinology. 1984 — GHRP/ghrelin receptor agonist mechanism
3. PNAS. Discovery of a functionally selective ghrelin receptor (GHSR1a) ligand. 2022 — β-arrestin mediated GHSR1a desensitization mechanism
4. Veldhuis JD et al. Somatostatin inhibition of GHRH-stimulated GH secretion. J Clin Endocrinol Metab — 86% GHRH pathway inhibition after exogenous GH
5. Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. NEJM. 2007 — Tesamorelin 26-week clinical trial efficacy

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness